Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Milestone Pharmaceuticals Inc.

Ticker
MIST
Sector
Industry
Report date
November 13, 2026
Valye AI Score

71

High visibility
Recent developments
Recent developments summary

Recent developments include regulatory approvals in China for Etripamil nasal spray, initiation and progress of Phase 3 trials for AFib-RVR treatment, launch of CARDAMYST in the U.S., and receipt of Nasdaq non-compliance notice due to share price.

Recent developments:
  • Milestone Pharmaceuticals received a Nasdaq notice of non-compliance under Rule 5450(a)(1) due to its common share price falling below $1.00 for 30 consecutive business days, with a compliance period until April 21, 2027 [N1].
  • The company obtained China regulatory approval for Etripamil nasal spray for PSVT, triggering milestone payments [N4][N5].
  • Milestone launched CARDAMYST, the first self-administered FDA-approved PSVT therapy [N3].
  • Phase 3 trial enrollment for Etripamil as a self-administered treatment for AFib-RVR is underway, including first patients in Canada and Europe [N3].
  • Q2 2026 earnings reported a net loss of $25.8 million and revenue of $2.96 million, with EPS of -$0.18 [N6][N7][N8].
  • The company announced cost-efficiency measures in November 2026 to reduce operational expenses by approximately 30%, including a 20% workforce reduction to extend cash runway [S2].
Overview

Milestone Pharmaceuticals Inc. develops and commercializes treatments for cardiovascular conditions. Its lead product, Etripamil nasal spray, is approved in China for PSVT and has received FDA approval in the U.S. as CARDAMYST, the first self-administered treatment for PSVT. The company is advancing a Phase 3 trial for Etripamil targeting AFib-RVR. Milestone's financials as of Q3 2026 show ongoing net losses but strong liquidity. The company faces Nasdaq listing compliance challenges due to share price but is implementing cost reductions to manage expenses.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Milestone Pharmaceuticals Inc. is a pharmaceutical company focused on cardiovascular treatments, notably Etripamil nasal spray for PSVT and AFib-RVR. The company has regulatory approvals in China and has launched CARDAMYST, the first self-administered FDA-approved PSVT therapy. Milestone is conducting Phase 3 trials for Etripamil with ongoing patient enrollment. As of September 30, 2026, the company reported a net loss of $25.8 million and revenue of $2.96 million, with strong liquidity indicated by a current ratio of 6.27. The company received a Nasdaq notice of non-compliance due to share price below $1.00, with a compliance period until April 2027, and has initiated cost-efficiency measures including workforce reductions to extend cash runway.

Scenarios for MIST

Bull case model:

Milestone's regulatory approvals and product launches for Etripamil nasal spray in multiple jurisdictions demonstrate commercial viability. Ongoing Phase 3 trials and patient enrollment progress support continued clinical development. Strong liquidity and cost-efficiency initiatives may provide operational stability to support execution milestones.

Bear case model:

The company faces risks from Nasdaq non-compliance and potential delisting if share price does not recover, which could impair liquidity and financing options. Continued net losses and operational restructuring may impact execution. Clinical trial outcomes and regulatory approvals remain uncertain, posing risks to product commercialization and revenue growth.

Moat:

Milestone's moat is based on its pioneering development of self-administered nasal spray therapies for acute cardiovascular arrhythmias, including FDA and China regulatory approvals for Etripamil. Its proprietary formulation and clinical trial progress in AFib-RVR position it uniquely in a niche therapeutic area with limited direct competition for self-administered acute treatments.

Risks overview
Risks summary
The most significant risk is potential Nasdaq delisting due to share price non-compliance, which could materially affect liquidity, investor interest, and financing capabilities.
Risks details:

• Nasdaq Listing Compliance Risk: Milestone received a notice of non-compliance due to its common share price falling below $1.00 for 30 consecutive business days, with a deadline to regain compliance by April 21, 2027. Failure to comply could lead to delisting, reducing liquidity and financing ability [N1][S2].
• Operational Risks from Workforce Reduction: The company is implementing cost-efficiency measures including a 20% workforce reduction to extend cash runway. This may lead to loss of institutional knowledge, decreased morale, and challenges in redistributing duties, potentially adversely affecting operations [S2].
• Clinical and Regulatory Risks: Milestone's business depends on successful clinical trial outcomes and regulatory approvals for Etripamil in various indications. Delays or negative results could impact commercialization and financial performance.

FINAL FORECAST FOR MIST

Final take one line
Milestone Pharmaceuticals has high visibility through regulatory approvals, clinical progress, and detailed financial disclosures but faces Nasdaq compliance and operational risks.
Final take 12 to 24 month view

Business trends: Regulatory approvals for Etripamil and clinical trial progress in AFib-RVR highlight ongoing development in cardiovascular therapies.
Execution milestones: Completion of Phase 3 trials, commercialization of CARDAMYST, and successful Nasdaq compliance are key execution points.
Key risks: Nasdaq delisting risk, operational challenges from workforce reductions, and clinical/regulatory uncertainties remain significant.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

71
LLM visibility overview
LLM Visibility known facts
  • Milestone Pharmaceuticals Inc. is a pharmaceutical company focused on developing treatments for cardiovascular conditions, notably with its product Etripamil nasal spray.
  • The company has received regulatory approvals for Etripamil nasal spray in China for PSVT (paroxysmal supraventricular tachycardia) treatment, triggering milestone payments [N4][N5].
  • Milestone launched CARDAMYST, the first self-administered FDA-approved PSVT therapy [N1][N3].
  • The company is conducting a Phase 3 trial (ReVeRA-301) for Etripamil as a self-administered treatment for AFib-RVR (atrial fibrillation with rapid ventricular response), with enrollment ongoing including first patients in Canada and Europe [N3].
  • Milestone reported Q2 2026 financial results showing a net loss of $25.8 million and revenue of $2.96 million for the quarter ending September 30, 2026, with basic and diluted EPS of -$0.18 [S2][N6][N7][N8].
  • As of September 30, 2026, the company had $144.5 million in cash and equivalents, $0.88 million in short-term investments, current assets of $161.6 million, and current liabilities of $25.8 million, resulting in a current ratio of 6.27 and a cash ratio of 5.64, indicating strong liquidity [S2].
  • Milestone received a Nasdaq notice of non-compliance under Rule 5450(a)(1) due to its common share price falling below $1.00 for 30 consecutive business days, with a compliance period until April 21, 2027 [N1][S2].
  • The company announced cost-efficiency measures in November 2026 to reduce operational expenses by approximately 30%, including a workforce reduction of about 20%, aiming to extend cash runway through the anticipated topline results of the AFib-RVR Phase 3 trial in the second half of 2028 [S2].
  • Risks include potential delisting from Nasdaq if share price compliance is not regained, which could reduce liquidity and financing ability, and operational risks related to workforce reductions and restructuring [S2].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
  • N6
  • N7
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-20 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-10-29 | www.nasdaq.com | Milestone Pharmaceuticals Inc. Receives Nasdaq Notice of Non-Compliance Under Rule 5450(a)(1) | https://www.nasdaq.com/articles/milestone-pharmaceuticals-inc-receives-nasdaq-notice-non-compliance-under-rule-5450a1
  • N2 | 2026-10-09 | www.nasdaq.com | Sagimet Reports Sustained Acne Improvements With Denifanstat Through 52 Weeks | https://www.nasdaq.com/articles/sagimet-reports-sustained-acne-improvements-denifanstat-through-52-weeks
  • N3 | 2026-09-04 | www.nasdaq.com | Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals | https://www.nasdaq.com/articles/weekly-buzz-ions-mist-biib-azn-win-nods-tcrx-nvs-cut-jobs-ovid-vir-data-regn-pasg-deals
  • N4 | 2026-09-03 | www.nasdaq.com | Milestone Gets China Approval For Etripamil Nasal Spray | https://www.nasdaq.com/articles/milestone-gets-china-approval-etripamil-nasal-spray
  • N5 | 2026-09-03 | www.nasdaq.com | Milestone Pharma Announces Approval Of Etripamil Nasal Spray In China; Triggers Milestone Payment | https://www.nasdaq.com/articles/milestone-pharma-announces-approval-etripamil-nasal-spray-china-triggers-milestone-payment
  • N6 | 2026-08-19 | www.nasdaq.com | Milestone (MIST) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/milestone-mist-q2-2026-earnings-call-transcript
  • N7 | 2026-08-12 | www.nasdaq.com | Milestone Pharmaceuticals Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/milestone-pharmaceuticals-q2-earnings-call-highlights
  • N8 | 2026-08-12 | www.nasdaq.com | Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/milestone-pharmaceuticals-mist-reports-q2-loss-lags-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine